Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quoin PharmaceuticalsSTU:2EB0 19 Cash Ratio is 2.63 as of Mar. 2026, which is 11% below its 10-year median of 2.97. GuruFocus rates STU:2EB0 with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,381 Biotechnology companies, Quoin Pharmaceuticals ranks worse than 53.66% on this metric.
Quoin Pharmaceuticals has a Cash Ratio of 2.63. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Quoin Pharmaceuticals's Cash Ratio or its related term are showing as below:
STU:2EB0'
s Cash Ratio Range Over the Past 10 Years
Min: 0.04 Med: 2.97 Max: 4.21
Current: 2.63
During the past 7 years, Quoin Pharmaceuticals's highest Cash Ratio was 4.21. The lowest was 0.04. And the median was 2.97.
STU:2EB0's Cash Ratio is ranked worse than 53.66% of 1381
companies
in the Biotechnology industry
Industry Median: 2.95
vs STU:2EB0: 2.63
Quoin Pharmaceuticals (STU:2EB0) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2EB0 vs VTGN, SYBX, APRE: Cash Ratio Comparison
For the Biotechnology subindustry, Quoin Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quoin Pharmaceuticals Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Quoin Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Quoin Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quoin Pharmaceuticals (STU:2EB0) has a Cash Ratio of 2.63 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Quoin Pharmaceuticals and its competitors. This is 11% below median its historical median of 2.97. Over the past decade, Quoin Pharmaceuticals' Cash Ratio has ranged from 0.04 to 4.21. According to the industry distribution chart, Quoin Pharmaceuticals ranks #741 out of 1381 companies in the Biotechnology industry, placing it in the top 53.7%.
Is Quoin Pharmaceuticals' Cash Ratio too high?
Quoin Pharmaceuticals' current Cash Ratio of 2.63 is 11% below median its 10-year median of 2.97. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 4.21. The Biotechnology industry median Cash Ratio is 2.95. Quoin Pharmaceuticals' value of 2.63 is 10.8% below this industry median. Based on the distribution chart, Quoin Pharmaceuticals ranks #741 out of 1381 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Quoin Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Quoin Pharmaceuticals' Cash Ratio compare to VTGN and SYBX?
According to the Biotechnology industry distribution chart, Quoin Pharmaceuticals ranks #741 out of 1381 companies for Cash Ratio. This places Quoin Pharmaceuticals in the lower half of its industry. The industry median Cash Ratio is 2.95. Quoin Pharmaceuticals' value of 2.63 is 10.8% below this benchmark. Historically, Quoin Pharmaceuticals' own Cash Ratio has ranged from 0.04 to 4.21 over the past decade. While the company's 10-year median is 2.97 vs. the industry median of 2.95, Quoin Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.95, based on 1,381 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quoin Pharmaceuticals's current Cash Ratio of 2.63 is 10.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Quoin Pharmaceuticals and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quoin Pharmaceuticals's current Cash Ratio is 2.63, which is 11% below median its own 10-year median of 2.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quoin Pharmaceuticals stock overvalued right now?
Quoin Pharmaceuticals (STU:2EB0) has a current Cash Ratio of 2.63. The current Cash Ratio is 2.63, which is 11% below median its 10-year median of 2.97 and 10.8% below the Biotechnology industry median of 2.95. Quoin Pharmaceuticals' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Quoin Pharmaceuticals (STU:2EB0), the current Cash Ratio is 2.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
19GF Score
Get the complete analysis for STU:2EB0
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2EB0 has been successfully added to your 
